Skip to Content

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

PEACE-1 phase 3 trial is the first prospective assessment of bone mineral density in a randomized trial implementing experimental treatment with abiraterone plus prednisone. In this MEDtalk Dr Guilhem Roubaud presents the results of the study, and explains why bone mineral density should be carefully assessed in patients with de novo metastatic castration-sensitive prostate cancer.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top